Xalatamax, eye drops 0.005% 2.5ml 3 pcs

Antiglaucoma drug for topical use. Latanoprost is an analogue of prostaglandin F_2α and a selective agonist of FP-receptors.

Latanoprost reduces intraocular pressure by increasing outflow of aqueous humor and has anti-glaucoma effect. The main mechanism of action of latanoprost is related to the increase of uveoscleral outflow.

It has no reliable effect on aqueous humor production and does not affect the heme-ophthalmic barrier.

The decrease of intraocular pressure starts 3-4 hours after administration of the drug with maximal effect noted after 8-12 hours and the duration of action at least 24 hours.

Indications

Reduction of elevated intraocular pressure (IOP) in adults and children (over 1 year of age) with open-angle glaucoma or increased ophthalmotonus.

Pharmacological effect

Antiglaucoma drug for local use. Latanoprost is a prostaglandin F2α analog and a selective FP receptor agonist.

Reduces intraocular pressure by increasing the outflow of aqueous humor and has an antiglaucoma effect. The main mechanism of action of latanoprost is associated with an increase in uveoscleral outflow.

It does not have a significant effect on the production of aqueous humor and does not affect the blood-ophthalmic barrier.

The decrease in intraocular pressure begins 3-4 hours after administration of the drug, the maximum effect is observed after 8-12 hours, the duration of action is at least 24 hours.

Special instructions

Latanoprost may cause a gradual change in eye color by increasing the amount of brown pigment in the iris.

This effect is detected predominantly in patients with mixed iris color, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in the melanin content in the stromal melanocytes of the iris.

Typically, brown pigmentation extends concentrically around the pupil to the periphery of the iris, and the entire iris or parts of it may become a more intense brown color. In patients with evenly colored eyes of blue, grey, green or brown, changes in eye color were observed very rarely after two years of use of the drug.

The color change is not accompanied by any clinical symptoms or pathological changes.

After discontinuation of the drug, no further increase in the amount of brown pigment was observed, however, the color change that has already developed may be irreversible. In the presence of nevi or lentigines on the iris, no changes were noted under the influence of therapy.

Active ingredient

Latanoprost

Composition

Active substance:

latanoprost – 0.050 mg.

Excipients:

benzalkonium chloride – 0.20 mg;

sodium dihydrogen phosphate monohydrate – 4.60 mg;

sodium hydrogen phosphate – 4.74 mg;

sodium chloride – 4.10 mg;

purified water – 996.31 mg.

Pregnancy

Use during pregnancy is contraindicated.

If it is necessary to use the drug, breastfeeding should be stopped.

No effect of latanoprost on male or female fertility was found in animal studies.

Contraindications

Hypersensitivity to latanoprost or other components of the drug.
Age up to 1 year (efficacy and safety have not been established).

Side Effects

From the side of the organ of vision:

Eye irritation (burning sensation, feeling of sand in the eyes, itching, tingling and foreign body sensation), blepharitis, conjunctival hyperemia, eye pain, increased pigmentation of the iris, transient pinpoint erosion of the epithelium, swelling of the eyelids, swelling and erosion of the cornea, conjunctivitis, elongation, thickening, increase in the number and intensification of pigmentation of eyelashes and vellus hair, iritis/uveitis, keratitis, macular edema (including cystoid), change in the direction of eyelash growth, sometimes causing eye irritation, blurred vision. Anchor: #Dermatologicheskie_reakcii

Dermatological reactions: Rash, darkening of the skin of the eyelids and local skin reactions of the eyelids.

From the nervous system: Dizziness, headache.

From the respiratory system: Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), shortness of breath.

From the musculoskeletal system: Muscle pain, joint pain.

Other: Nonspecific chest pain.

Interaction

Latanoprost has an additive effect in reducing intraocular pressure when used in combination with beta-blockers, adrenergic agonists, carbonic anhydrase inhibitors and a partial additive effect when used in combination with m-cholinomimetics.

In vitro studies have revealed that when eye drops containing thiomersal are mixed with latanoprost, precipitation occurs. Therefore, eye drops containing these substances should be used at intervals of at least 5 minutes. The simultaneous use of 2 prostaglandin analogues can cause a paradoxical increase in intraocular pressure.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episclera.

Treatment: carry out symptomatic therapy.

Storage conditions

Store in a dry place, protected from light, at a temperature of 2 to 8ºС.

Store an open bottle at a temperature not exceeding 25ºС.

Shelf life

1 year

Manufacturer

JADRAN-GALENSKI LABORATORY j.s., Croatia